Taysha Gene Therapies Inc (TSHA) Stock Experiences -13.65% Monthly Change

In the past week, TSHA stock has gone down by -1.27%, with a monthly decline of -13.65% and a quarterly surge of 68.35%. The volatility ratio for the week is 6.94%, and the volatility levels for the last 30 days are 7.50% for Taysha Gene Therapies Inc. The simple moving average for the past 20 days is -9.02% for TSHA’s stock, with a 17.67% simple moving average for the past 200 days.

Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA) Right Now?

The 36-month beta value for TSHA is also noteworthy at 0.95. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for TSHA is 213.50M, and at present, short sellers hold a 15.58% of that float. The average trading volume of TSHA on July 02, 2025 was 3.86M shares.

TSHA) stock’s latest price update

Taysha Gene Therapies Inc (NASDAQ: TSHA)’s stock price has gone rise by 1.30 in comparison to its previous close of 2.31, however, the company has experienced a -1.27% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-06-06 that DALLAS, June 06, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha’s Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company’s common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Analysts’ Opinion of TSHA

Many brokerage firms have already submitted their reports for TSHA stocks, with BMO Capital Markets repeating the rating for TSHA by listing it as a “Outperform.” The predicted price for TSHA in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on June 27, 2024 of the previous year 2024.

Piper Sandler, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $9. The rating they have provided for TSHA stocks is “Overweight” according to the report published on April 09th, 2024.

Jefferies gave a rating of “Hold” to TSHA, setting the target price at $1.50 in the report published on February 01st of the previous year.

TSHA Trading at -3.31% from the 50-Day Moving Average

After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.31% of loss for the given period.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 750,000 shares at the price of $2.75 back on May 30 ’25. After this action, Manning Paul B now owns 2,841,704 shares of Taysha Gene Therapies Inc, valued at $2,062,500 using the latest closing price.

Stock Fundamentals for TSHA

Current profitability levels for the company are sitting at:

  • -12.26 for the present operating margin
  • 0.73 for the gross margin

The net margin for Taysha Gene Therapies Inc stands at -12.01. The total capital return value is set at -0.76. Equity return is now at value -159.34, with -59.56 for asset returns.

Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -4.88. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -1639.81.

Currently, EBITDA for the company is -87.95 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 60.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.35.

Conclusion

In summary, Taysha Gene Therapies Inc (TSHA) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts

favicon-nh
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.